Purchase Order HHSN272201301160P

<p>This is a firm-fixed-price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Alpha Diagnostic International Inc., a woman-owned small business. The order is for the procurement of 12 bulk kits of the AMBIS # 1774444 Human Anti-Zaire Ebola Virus Glycoprotein (GP) IgG ELISA Kit, 96 tests quantitative. The total ceiling value of the award is $69,910.00, with a completion date of June 16, 2016. This award does not have a set-aside designation.</p>

This is a $10,495 firm fixed price delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Alpha Diagnostic International Inc., a minority-owned, woman-owned small business. The contract is for the procurement of 20 units of the AMBIS # 1768645 Human Anti-Zaire-Ebola Virus Glycoprotein (GP) IgM ELISA Kit at a unit price of $516.00. The contract has a completion date of June 16, 2016 and was awarded on December 4, 2015. This contract does not have a...

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Boston Bioscience Inc. for $13,150.00 on August 30, 2017. The order procures Ebola peptides, seven residues. Work is performed in Royal Oak, Michigan. The order has an ultimate completion date of August 29, 2018.</p>

This is a federal purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Bio-Synthesis, Inc., a for-profit manufacturer of goods. The contract is for the supply of CUST.PEP.1,MISK...AGVAN-19, 1MG,&gt;95% PURE with a ceiling value of $3,655.00. The contract was awarded on October 11, 2011, with a completion date of November 10, 2011, and has a firm fixed price pricing type. This...

This is a firm fixed price delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Alpha Diagnostic International Inc., a minority-owned, woman-owned small business. The contract is for the provision of a Human Anti-Zaire Ebola Virus Nucleoprotein (NP) IgG ELISA Kit, a quantitative 96-test kit. The contract has a ceiling value of $7,501.00 and a period of performance ending on May 22, 2016. The contract was awarded on April 22, 2016...

The Office of the Assistant Secretary for Preparedness and Response awarded a definitive contract to Mapp Biopharmaceutical, Inc. for procurement of therapeutics for Ebola, Sudan, and Marburg viruses, with a ceiling value of $942.8 million and a cost-plus-fixed-fee pricing structure. The contract carries an ultimate completion date of September 29, 2032. Place of performance is San Diego, CA. This award represents a modification providing supplemental funding of $322,131 for CLIN 00013 and a...

<p>The National Institute of Allergy and Infectious Diseases issued a purchase order to JPT Peptide Technologies GMBH on March 9, 2018, for $19,911.00 to manufacture 156 custom synthesized overlapping peptides for the target antigen HIV-BG-505. The order carries a firm fixed price structure with no set-aside designation. Work is performed in Germany and must be completed by April 9, 2018.</p>

This is a $293,443,870.00 definitive contract awarded by the Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) to Mapp Biopharmaceutical, Inc., a San Diego-based biotechnology company. The contract is for the provision of therapeutic interventions and medical countermeasures against infectious diseases and biothreats, including viral hemorrhagic fevers like Ebola, Marburg, and Lassa, as well as botulinum neurotoxin. Mapp...

The Office of the Assistant Secretary for Preparedness and Response awarded a $166.898 million definitive contract to International AIDS Vaccine Initiative Inc. for the advanced development of monovalent vaccines for prevention of Marburg Virus and Sudan Ebolavirus on September 30, 2021, with performance extending through December 31, 2028. The contract advances vaccine candidates based on recombinant expression of filovirus glycoproteins. Place of performance is New York, NY 10004. The...

This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Ebioscience, Inc., a for-profit organization. The contract has a total ceiling value of $7,551 and was awarded on June 26, 2012 with a completion date of July 25, 2012. The contract does not have a set-aside designation. Ebioscience, Inc. is a subsidiary of the parent company Affymetrix, Inc., another for-profit organization that has also been awarded...